Objective To determine the extent of off-label and unlicensed prescribing in hospitalized newborns and to identify patientrelated risk factors associated with off-label prescribing. Methods A prospective cohort study was conducted between January and March 2016 at a neonatology department of a tertiary-care hospital in the Eastern province. All consecutive admissions to all neonatal care levels meeting the inclusion and exclusion criteria were eligible for enrollment. All prescriptions were classified as off-label or unlicensed according to drug product monograph. Clinical and prescription data were extracted using a pilot-tested structured data collection sheet. Results During the study period 583 prescriptions were made for 138 newborns, of which 29.7% (173/583) and 12.9% (75/583) were classified as off-label and unlicensed drugs respectively for use in neonates. Thirty-four percent (47/138) of patients received at least one off-label/unlicensed medicine. Mechanical ventilation, admission to the neonatal intensive care unit and length of hospital stay were identified as independent risk factors associated with prescribing of at least one off-label medication. Conclusion Use of off-label and unlicensed drugs in hospitalized newborns seems to be a common practice in this Saudi hospital. Future research should evaluate safety and efficacy of off-label and/or unlicensed use of drugs in neonates.
Introduction
Safe prescribing is particularly challenging in neonatal patients because most of the therapeutic agents have not been studied in this patient population and their benefit versus risk ratio is often supported by limited evidence [1] . Unlicensed (UL) use refers to 'using drugs that are not specifically licensed for use in pediatric population' and off-label use refers to 'using a drug outside the terms of their product license'; i.e., different indication, age range, dose or route of administration [2] .
Unlicensed or off-label use of drugs is often associated with certain safety problems. Off-label and unlicensed use of drugs is more likely to lead to medication errors causing harm in children [3] . Furthermore, it has been estimated that off-label or unlicensed use of medicines accounts for between 23 and 60% of all ADRs in children [4] . However, off-label and/or unlicensed use may not necessarily be always incorrect, but instead necessitated by certain medical conditions. Saudi Food and Drug Authority (SFDA) is the governmental agency that regulates drug licensing in the Kingdom. Pharmaceutical companies are only allowed to promote licensed medicines for approved medical conditions [1] . Prescribers, however, are free to prescribe the most appropriate medicine for their patients. To the best of our knowledge, no study has examined the pharmacoepidemiology of unlicensed and off-label drug use among hospitalized neonates in Saudi Arabia.
Aim of the study
The current study was designed to fill this research gap by investigating the extent of off-label and unlicensed prescribing in neonates admitted in neonatology department of a tertiary-care hospital in Saudi Arabia and to identify patientrelated risk factors associated with off-label prescribing.
Ethics approval
The institutional Clinical Research Ethics Committee granted ethics approval (Ref number: KFUH-DON-04/08/2015) and waived the requirement for obtaining informed consent for reviewing patients' medical records.
Methods

Study settings
The present study was conducted at the neonatology department of a tertiary care teaching hospital in the Eastern Province. The neonatology department consists of two well-newborn nurseries (each contains 25 beds/cribs), one special care nursery (contains 20 cribs/beds), and one neonatal intensive care unit (NICU) (contains 10 beds/cribs). Newborns are admitted to one of these nurseries/wards based on their clinical condition. Neonates were prospectively recruited from well-newborn nurseries, special care nursery and NICU between January and March 2016. The pharmacy department uses a closed drug formulary (a formulary covering a restricted, specific set of medications within each therapeutic class and require justification for use of drugs not listed on the formulary) developed in collaboration with the Pharmacy and Therapeutics Committee of the hospital.
Study population
All consecutive admissions to all neonatal care levels during the study duration were screened for eligibility. Neonatal patients admitted to any neonatal unit/nursery for a minimum of 24 h and prescribed with at least one drug were included in the study. Following drugs were also excluded: nutritional preparations, standard intravenous crystalloid solutions, oxygen and heparin used to maintain patency of intravenous lines.
Data collection
A structured data collection sheet was developed and pilottested to ensure uniformity in data collection. The recorded clinical variables included: birth weight, gestational age, gender, birth route, postnatal age, mechanical ventilation status, number and type and of medications administered. Data were extracted from electronic medical records by a clinical pharmacist. The following data were recorded for each drug prescription order: drug prescribed, drug formulation, route of administration, dose, frequency, and indication for a prescription. The treating physicians, resident doctors, and staff nurses were not aware of the nature and scope of this study.
The prescribed drugs were uniformly coded using WHO Anatomic Therapeutic Classification (ATC) [2] . All recorded medications were reviewed for Saudi FDA approval for use in neonates by using the product monograph for each drug as a reference. These prescriptions were classified into three groups, according to the criteria published by Turner [3] : approved prescriptions according to label, off-label prescriptions, and unlicensed prescriptions. We defined offlabel use as drug is being used in a way that is different to what described in the license. This may include drugs given for an approved indication, but in an unapproved manner, for example, those given at a higher dose, greater frequency, to an age group, or by a route not described in the product monograph or a licensed drug given for indications for which its use has not been approved. An unlicensed drug was defined as a drug without a product license to use in neonates [2] .
Statistical analysis
Data were analyzed using IBM SPSS version 21.0. software. Results for continuous variables are expressed as means and percentages. Univariate and multivariate logistic regression analyses were performed to identify factors associated with off-label use of medicines in neonates. Variables from univariate analysis with a P value of less than 0.20 were inserted into a multivariate logistic regression model to identify independent predictors of offlabel use of drugs in neonates. Odds ratio (OR) with 95% confidence interval (95% CI) were computed along with corresponding P value (P < 0.05). Table 1 shows demographic and clinical characteristics of the patients. During the 3-month study period, 138 patients [72 males (52%) and 66 females (48%)] were enrolled in the study. The mean (± SD) postnatal age was 12 (± 8) days. The overall mean (± SD) length of hospital stay was 7.8 (± 6) days. The median gestational age (IQR) of the patients was 37 (35-39) weeks with 12% (16/138) neonates were born preterm. More than two-thirds (81.1%; N = 112/138) of neonates were born with normal birth weight.
Results
Clinical characteristics of patients
Prevalence of off-label/unlicensed medications use
In total 583 prescriptions were made (mean 3.5 ± 2.3 per patient), related to 63 different drug products. The most common route of administration of drugs was intravenous (81%; N = 51/63) followed by oral (9.5%; N = 6/63), intramuscular (4.5%; N = 3/63), topical (3.1%; N = 2/63), and via an endotracheal tube (0.6% N = 1/63).
Of 583 prescriptions reviewed, 42.6% (N = 248) prescriptions had at least one drug for either an off-label (29.7%; N = 173/583) or unlicensed (12.9%; N = 75/583) use. Thirtyfour percent (N = 47/138) of patients received at least one off-label/unlicensed medicine. Five percent of the total prescriptions (N = 29/583) had both off-label and unlicensed drugs. The number of off-label and unlicensed prescriptions per patient ranged from 0 to 5 (mean 2.24 ± 1.7) and from 0 to 2 (mean 0.29 ± 0.6), respectively. Administration of drug outside licensed age range (37%; N = 64/173) was the most common category of off-label prescription followed by greater dose (25%; N = 43/173), administration for indication outside licence (16.5%; N = 29/173), frequency (more frequent) (11%; N = 19/173), formulation outside license (6.5%; N = 11/173), and alternative routes of administration outside license (4%; N = 7/173). Piperacillin/tazobactam was the most frequently prescribed the off-label drug in 'outside licensed age range' category. The therapeutic class of off-label used drugs according to the WHO Anatomical Therapeutic Chemical (ATC) classification included: antiinfectives (34%), alimentary tract and metabolism (23%), nervous system (19%) and cardiovascular system (14%). A few examples of the most commonly prescribed drugs in an off-label manner include ranitidine, midazolam, tobramycin, salbutamol and fluconazole. The most frequently prescribed drugs used in an unlicensed manner were polystyrene sulfonate and mannitol.
Risk factors associated with off-label drug use in neonates
Multivariate logistic regression analysis found mechanical ventilation (OR 1.91; 95% CI 1.36-2.34), admission in NICU (OR 1.79; 95% CI 1.25-2.93) and length of hospitalisation (OR 1.57; 1.45-1.93) to be the independent patientrelated risk factors associated with increased use of off-label drugs ( Table 2) .
Discussion
To best of our knowledge, this is the first study to assess the off-label and unlicensed use of medicines among neonates in the Kingdom of Saudi Arabia. In the present study, 42.5% of all prescriptions contained at least one off-label or unlicensed drug. In literature, the use of unlicensed and offlabel medications in neonates ranges between 35 and 75% [4] . The wide differences in the literature can be attributed to variations in the definitions of off-label and unlicensed drugs used and heterogeneity in the studied patient population. The relatively less use of off-label and unlicensed drug in this study compared to previous studies [4] is probably because we recruited patients from three levels of care (Level 1: well-newborn nursery; Level II: special care nursery, and Level III NICU), with a high percentage of patients from well-newborn nursery. Furthermore, some of the previous studies [4] had included blood products, intravenous fluids, and nutritional supplements, unlike the present study. Our results showed that newborn infants in NICU and those mechanically ventilated infants were 1.8 and 1.9 times more likely to be prescribed drugs for off-label use, respectively. These results are consistent with data from other countries [5, 6] . Studies conducted exclusively in NICUs showed that preterm and neonates with low birth weight are most vulnerable to receive more drugs than the mature ones [5] . However, birth weight was not found to be an independent predictor associated with off-label use in neonates in this study.
We identified that systemic antibacterials were the most frequently used off-label drugs, followed by drugs that act on gastrointestinal and central nervous systems. Previous studies also reported a greater off-label utilization of antibiotics [4] . Among antibacterials group, piperacillin/tazobactam was the most frequently prescribed drug for off-label use. Among gastrointestinal drugs, ranitidine was the most frequently prescribed off-label drug despite safety concerns. A recent study has shown ranitidine use in newborns in NICU was associated with an increased risk of infections and mortality [7] . In line with the findings of a recent systematic review [4] , which estimated unlicensed drug use in hospitalized neonates between 0.2 and 36%, 12.9% of the prescriptions in our study had at least one drug prescribed in an unlicensed manner.
Limitations
Since this study was conducted only in one neonatology department, the findings may not be generalizable to other secondary or tertiary care hospitals in Saudi Arabia. Our study was only aimed at determining the extent of off-label and unlicensed use of drugs in neonates and did not assess benefits and harms (adverse effects) associated with off-label and unlicensed use. Future research should explore this issue further. Finally, we only identified risk factors for off-label use but not for unlicensed use as the number of patients receiving drugs in an unlicensed manner was too little to do meaningful statistical analysis.
Conclusion
Use of drugs in an off-label and/or unlicensed manner in hospitalised neonates is a common practice in this Saudi hospital. The proportion of drugs used in an off-label manner was more common than in an unlicensed manner. Healthcare professionals should carefully assess benefits and risks associated with the off-label and unlicensed use of drugs in neonates.
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